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ABSTRACT

DEVELOPMENT OF INFORMATIVE PRIORS IN MICROARRAY STUDIES

Kassandra M. Fronczyk
Department of Statistics
Master of Science

Microarrays measure the abundance of DNA transcripts for thousands of gene
sequences, simultaneously facilitating genomic comparisons across tissue types or disease status. These experiments are used to understand fundamental aspects of growth
and development and to explore the underlying genetic causes of many diseases.
The data from most microarray studies are found in open-access online databases.
Bayesian models are ideal for the analysis of microarray data because of their ability
to integrate prior information; however, most current Bayesian analyses use empirical or flat priors. We present a Perl script to build an informative prior by mining
online databases for similar microarray experiments. Four prior distributions are investigated: a power prior including information from multiple previous experiments,
an informative prior using information from one previous experiment, an empirically
estimated prior, and a flat prior. The method is illustrated with a two-sample experiment to determine the preferential regulation of genes by tamoxifen in breast cancer
cells.
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1. INTRODUCTION

The study of differential expression is important for understanding biological
processes because it provides information about which proteins are produced in a
cell. Knowledge of protein expression provides clues about the functions of particular
genes, allows identification of clusters of related genes, and motivates new hypotheses
and experiments. Protein expression is difficult to measure reliably; consequently,
mRNA expression levels serve as a reasonable surrogate. For example, recognizing
which genes are differentially expressed in cancer cells and normal cells can give some
information about cancer.
Until recently, monitoring the simultaneous expression level of thousands of
genes in a single experiment was not possible. The Southern blot is a method for
searching for a specific DNA molecule. The Southern blot, proposed in 1975, introduced a one-to-one correspondence between clones and hybridization signals. After
the invention of the Southern blot, the use of non-porous solid supports and the development of methods for high-density spatial synthesis of oligonucleotides opened up
the world of DNA microarray technologies (Lander 1999), which provides expression
measurements for thousands of genes at once (Duggan et al. 1999, Shena et al. 1995).
Because patterns in which a gene is expressed can be temporal, developmental, and
physiological, the factors studied could be different types of tissues, drug treatments,
or time points of a biological process.
Considering the microarray community’s willingness to share data, the Bayesian
framework seems to be a logical approach to the analysis of these experiments; however, most of the current Bayesian analyses do not incorporate biological knowledge.
This thesis presents a method for incorporating the information from previous studies
into an informative prior for a two-sample Bayesian t-test. Results are compared to
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the use of an empirical Bayesian-estimated prior.
An overview of the elicitation process is given in Chapter 2. This includes
the reasons behind elicitation, a discussion of different approaches to elicitation, and
the constraints and limitations of using elicited information. Chapter 3 considers
some of the current Bayesian methods for analyzing microarray data. Some of the
methods investigated are Efron’s empirical Bayes analysis, Lönnstedt and Speed’s
B-statistic, and Conlon’s hierarchical Bayesian model for pooling microarray studies.
Chapter 4 presents the case study, and the design and analysis goals of the experiment
are explained and the types of prior information available are discussed. Chapter 5
describes the proposed model and the Perl script for automation. Chapter 6 presents
the results from the analysis of ten genes and chapter 7 gives the conclusions.

2

2. ELICITING PRIOR INFORMATION

We live in an uncertain world, and probability risk assessment deals
as directly with that fact as anything we do. Uncertainty arises partly
because we are fallible. Mostly, however, uncertainty arises because
the world is not as simple as we would have it. The variability of
phenomena (including human technology, and often in spite of our
pet theories) yields the most uncertainty. —E. M. Dougherty (1993)
Probability has several common interpretations. One of the most common approaches is to interpret probability as an objective long-range frequency. A second
interpretation of probability is as a degree of belief, or epistemic probability. This
subjective approach suggests probability may be specific to each individual. The elicitation process allows a statistician to quantify individually held beliefs as a number
between zero and one. If an individual does not have complete knowledge about a
probabilistically well-defined event, that uncertainty can be represented as a probability distribution.
In any statistical analysis, there is some form of background, or prior, knowledge
available in addition to the data. Prior knowledge can be elicited from different places,
but the most reliable and worthwhile reference is an expert in the field (Kadane and
Wolfson 1998). Elicitation is used when estimates are needed on new, rare, or complex
phenomena; for forecasting and predictions; to interpret data; and to understand or
determine a problem-solving process. It can also include work in selecting or defining
the scope of the problem, work in refining the problem, and the processes involved
in arriving at a solution to the problem. This information is a representation of the
expert’s knowledge at a specific point in time; it can and should change when new
information becomes available. The knowledge elicitation process has a considerable
influence on the quality of the resultant prior knowledge.

3

2.1

Methods
A substantive expert has opinions and knowledge about his or her field. These

opinions can be given in terms of processes, scales, ranks, and countless other forms.
Through the elicitation process, an analyst may work with an expert to extract parameters of a family of probability distributions in an organized and logical manner.
As Savage (1971) explains, if two experts with the same knowledge are induced to
reveal their opinions, then the resulting probability distributions should be the same.
Most experts do not know the parameters of these distributions or how to express
their knowledge in probabilistic terms. A statistician must be able to pose intuitive
questions and discuss the subject matter with the expert to adequately define an intelligible prior distribution that captures the main ideas of the expert’s opinion while
integrating experience and knowledge of the literature. Kadane and Wolfson (1998)
examine the psychology of getting experts to express what they know in distributional form. Meyer and Booker (2001) present a systematic approach for eliciting this
expert knowledge.
Knowledge elicitation methods are classified according to how directly information is obtained from the expert. Indirect methods are used to obtain information
that cannot be easily expressed directly. Some indirect methods include construct
elicitation, document analysis, and laddering. Direct methods elicit the required information directly from the expert, and include interviewing, protocol analysis, and
simulation. These techniques are based on the assumption that the expert is able to
articulate his or her knowledge. This assumption is not always warranted, as some
tasks become automatic after years of repetition.
Construct elicitation methods obtain information about how the expert discriminates between entities in the problem domain. As an example, consider a 90-year-old
man who sits at the end of a manufacturing line to remove defective ball bearings.
From years of practice, he is able to run his fingers over the ball bearings and remove
4

the defective ball bearings without being able to express his basis for the rejection. He
is now retiring and his replacement must be trained. Using a sample of defective and
acceptable ball bearings, the inspector asks the elderly man to verbalize the perceptions influencing his acceptance or rejection of each bearing. This practice has been
applied with products ranging from clothing and chocolate, to injection molds and
machine faults, to ball bearings and steel ladles (Reeve et al. 2004). The most commonly used construct elimination method is Repertory Grid Analysis (Kelley 1955).
For this method, the expert is presented with a list of entities and is asked to describe
the similarities and differences between them. These similarities and differences are
used to determine important attributes of the entities. After evaluating the initial
list of attributes, the researcher works with the expert to assign ratings to each pair
of entities and attributes.
Document analysis gathers information from existing subject-area literature.
This method may or may not involve interaction with a human expert to confirm or
enhance this information. For example, literature is integrated in biology studies in
different ways: hand-curated pathways have been sufficient for assembling models in
numerous studies; literature is frequently accessed for concepts or functional relationships in databases like the Medical Subject Headings (MeSH) and Gene Ontologies
(GO); and mining text directly for specific types of information is becoming more
popular as text analytics methods become more accurate and accessible (Roberts
2006).
Laddering is a diagramming technique in which the analyst asks the expert
questions to systematically build a hierarchy of subject concepts. The analyst begins
by stating the name of a seed item from the subject field. Specific questions are used
to lead the expert through the task domain or hierarchy. This technique is useful
when the subject constructs are known but the interrelationships between them are
poorly understood. For example, when interviewing a manager on how to improve
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team performance, the interviewer starts with the term productivity and the manager
is asked a series of standard questions to find terms that are up, down, or lateral in
the hierarchy. To move down the hierarchy, the interviewer may ask for examples
of productivity; to move up, he may ask about what some same-level items have in
common; to move across the hierarchy, he may ask for examples of the upper-level
item apart from the same-level item.
These indirect techniques are often effective at obtaining information that is
not easily expressed. However, in some situations, these indirect methods do not
produce the information needed by the analyst. Instead, the analyst may use a direct
method to increase the quality of information and the possibility of error reduction.
The most common direct methods include interviewing, protocol analysis, simulation
studies, and prototyping.
Interviewing consists of asking the expert questions about the subject of interest
and how they perform their tasks. Interviews can be unstructured, semi-structured,
or structured. The success of an interview session is dependent on the questions
asked and the expert’s ability to articulate his or her knowledge; it is difficult to
know which questions should be asked, particularly if the interviewer is not familiar
with the subject matter.
Protocol analysis (Ericsson and Simon 1984) involves asking the expert to perform a task while “thinking aloud.” The intent is to capture both the actions performed and the mental process used to determine these actions. For example, a study
examines adults building a lifting device using a child’s construction set. Performance
evaluation considers specific actions, such as bolting two parts together. The analyst
categorizes verbal statements according to reference—the goals of a particular action
or the evaluation of the outcome of a test component. On the basis of the references,
actions can be grouped into behavioral traits, revealing a pattern of goal decomposition exercised by the problem solver. As with all of the direct methods, the success
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of the protocol analysis depends on the ability of the expert to describe why he or
she is making a decision. In some cases, the expert may not remember that things
are done a certain way. In many cases, the verbalized thoughts will only be a subset
of the actual knowledge used to perform the task. One method used to augment
this information is interruption analysis. For this method, the analyst interrupts the
expert at critical points in the task to ask questions about why a particular action is
performed.
Simulation methods use a computer system to reproduce a complex task. A
simulation attempts to mimic an abstract model of a particular system. These simulations are a useful part of modelling many systems in physics, biology, economics, and
engineering to gain insight into the operation of those systems. These techniques are
used to study the behavior of objects or systems that cannot be easily or safely tested
in reality. In simulation studies, the expert behaves as though a simulation is occuring. For example, with the Wizard-of-Oz technique, people may believe that they
are communicating with a piece of software although they are linked to an individual
that is trained to respond to the consumer’s actions.
In prototyping, the expert evaluates a prototype of the proposed system; this
is usually an iterative process as the system is refined. Storyboarding is a type of
paper prototyping. For example, customers, users, or developers start a software
development project by drawing pictures of the screens, toolbars, and other elements
they believe the software should provide. The group continues to evolve these ideas
until their requirements and details are finalized.
All of these elicitation methods require iteration. After drawing out parameters
for a well-defined and coherent prior, the analyst must give some sort of feedback to
the expert. The analyst can ask questions like, “If what you said is true, then . . .” and
include some information about the properties of the distribution. The expert may
agree or disagree and explain further what should happen in those terms. The analyst
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can continue asking the expert questions to further develop the prior distribution until
both the expert and the researcher are satisfied with its characteristics.
The usefulness of any of these elicitation approaches hinges on the analyst’s
ability to evoke truthful and accurate reports from the experts. Two methods that
have been used to encourage trustworthy explanations are scoring rules (Savage 1971)
and prediction-based elicitation (Grether 1980a). Scoring rules use incentives to motivate people to state the probability of a random outcome thoughtfully and truthfully.
Prediction-based elicitation pays people for accurately predicting random outcomes
and then uses these predictions to infer probabilities. For example, to instigate a
prompt response to better predict the advance of a potential bird flu epidemic, health
experts are being financed to place a wager on the spread of the bird flu. This motivates the experts to give their opinions truthfully and quickly.

2.2

Constraints and Limitations
The elicitation and interpretation of subjective probability is a controversial

area of statistics. Nau (2001) discusses whether or not it is even possible to elicit the
true probability or probability distribution and whether it makes any difference to
the statistical inference. Singpurwalla (2002) compares the Bayesian and frequentist
approaches to probability and their consequences. Mosleh and Bier (1996) question
whether an individual can be uncertain about a probability, separating uncertainty
about the underlying events from that of cognitive imprecision. Benson et al. (1995)
express that elicitation of probability requires both the formation of a belief and
the assessment of a probability that quantifies that belief. They believe that the
former process involves judgement and reasoning, while the latter process is purely
judgmental.
Berman (1988) examines some issues about subjective probability or personal
opinion probabilities. He suggests three additional reasons for the unreliability of
8

subjective probability estimates:
(1) People tend to extrapolate linearly from existing information. Many things
in the world are non-linear.
(2) Breakthroughs in technology or understanding are by definition unpredictable.
(3) People of vision have frequently, if not always, been in the minority.
Berman also suggests that human uncertainty does not necessarily decrease as knowledge increases.
Evans (2000) summarizes some of the philosophical issues in eliciting prior information:
Engineers who represent their degree-of-belief by probability must
be stout-hearted. Once you have gone through the simulations and
settled on a realistic expression of your prior beliefs, stick to them
and to the resulting afterwards belief, no matter what the actual
experimental outcome. Remember, you have already considered that
outcome in your extensive simulation. Do not let anyone convince you
to be “practical” or “realistic” on their terms. Assert yourself. Say
that you have been practical and realistic on a very sound, rational
basis.
If there is prior knowledge available, it can and should be used to fully analyze
the problem at hand. Many statisticians, including Evans, believe that incorporating
this information is a legitimate and logical approach to problem-solving.

2.3

Less Subjective Priors
In theory, the process of inference is simple. Inference involves two steps: the

assertion of hypotheses and their proper organization. Thus, there is only one process of validating a conclusion. Many people are uncomfortable with the Bayesian
approach to inference because it does not follow a straightforward line of reasoning.
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They view the selection of a prior as arbitrary and subjective; however, priors may
be chosen to make selection more objective.
A famous example of the use of an objective prior can be found in Mosteller
and Wallace (1963). In this paper, Mosteller and Wallace conduct an analysis of
the twelve Federalist papers of unknown authorship. The Federalist Papers written
by Madison and Hamilton provide weighted prior distributions of word usage. Using
these long-range frequencies as the prior distributions for the negative binomial model,
the authors conclude that Madison, rather than Hamilton, wrote all twelve of the
disputed papers.
There are other examples of using less subjective priors. Many current Bayesian
methods for the analysis of microarray experiments assume normality of the logexpression ratios and include reference priors on one or more of the hyperparameters.
The authors of such examples claim ignorance of the information about the genome
and include broad guesses for the values of the prior distributions. For instance,
Conlon et al. (2006) assume that any given gene has a uniform chance of differential
expression. Another approach to building a less subjective prior is using information
from previous studies.
2.3.1

Power Priors
When existing data is available, a prior may be constructed from this data.

Ibrahim and Chen (2000) present a power prior for situations in which historical data
are available. The power prior is defined as the likelihood function based on the
historical data D0 raised to a power a0 , where 0 ≤ a0 ≤ 1 is a parameter that controls
the influence of the historical data on the current data. Historical data, denoted by
D0 = (n0 , X0 ), may be combined with the prior distribution for θ before the historical
data D0 is observed, π(θ|·). A prior distribution for a0 to obtain the joint power prior
distribution for (θ, a0 ) is
10

π(θ, a0 |D0 ) ∝ L(θ|D0 )a0 π0 (θ|c0 )π(a0 |γ0 ),
where c0 is a specified hyperparameter for the initial prior and γ0 is a specified hyperparameter vector. In most cases, c0 is defined to be one (Tsodikov et al. 2003; Fu
et al.2005; Ghosh et al. 2004). A natural choice for π(a0 |γ0 ) is a beta prior. Other
choices, including a truncated gamma prior or a truncated normal prior, have similar
theoretical properties, and similar computational properties can be chosen instead
of the beta distribution. According to Ibrahim and Chen, the proposed distributions yield similar results when the hyperparameters are appropriately chosen so the
distributions look similar.
Ibrahim and Chen (2000) show that the joint power prior distribution is proper
even if π0 (θ|c0 ) is chosen to be an improper uniform prior. This power prior can easily
be extended to the situation where there are multiple previous studies. If L0 is the
number of historical studies, then D0k = (n0k , X0k ) is the historical data based on the
kth study, k = 1, . . . , L0 and D0k = (D01 , D02 , . . . , D0L0 ). Then, Ibrahim and Chen
define a weight parameter a0k for each historical study, and take the a0k values to be
independent and identically distributed beta random variables with hyperparameters
γ0 = (δ0 , λ0 ), k = 1, . . . , L0 . Letting a0 = (a01 , . . . , a0L0 ), the power prior can be
expressed as

π(θ, a0 |D0 ) ∝

L0
Y

k=1

(L(θ|D0k )a0k π(a0k |γ0 )) π0 (θ|c0 ).

(2.1)

This approach enables the analyst to include previous studies in a simple manner.
The power prior is informative, yet not necessarily subjective.
Elicitation of reliable prior information is difficult; consequently, many statisticians use uninformative prior distributions in Bayesian analyses. For science to
progress, analyses must recognize prior experiments and formalize the information
11

gained for use in subsequent experiments.
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3. BAYESIAN METHODS FOR MICROARRAY EXPERIMENTS

Frequentist approaches are commonly used for the analysis of microarray experiments. Inference proceeds by stating a hypothesis and collecting data that will
either support or oppose the claim. A suitable model is chosen to fit the data. This
model allows the analyst to make inferences about the hypothesis. While frequentist
procedures are associated with probability statements about how procedures behave
across repeated measurements, Bayesian inference aims instead at making probability
statements given a particular measurement or set of measurements.
Bayesian inference is an approach to statistics in which all forms of uncertainty
are expressed in terms of probability. A Bayesian approach to a problem starts with
the formulation of a model that is hopefully adequate to describe the situation of
interest. A prior distribution is formulated over the unknown parameters of the
model, which is meant to help form beliefs about the situation before seeing the data.
After observing some data, Bayes’ Rule is applied to the data to obtain a posterior
distribution for the unknown parameters, which takes account of both the prior and
the data. From this posterior distribution, probability statements and predictive
distributions for future observations can be computed.
In the microarray setting, models often calculate the posterior probability of a
gene being differentially expressed. There are many different interpretations of what
may form a suitable model and distributions reflecting prior knowledge, resulting in
different approaches to the analysis of microarray data.

3.1

Empirical Bayes Models
The large number of genes and small sample size of typical microarray experi-

ments yield inflated t-statistics and a high rate of false discoveries. Table 3.1 provides
13

an example of a microarray experiment with three control and three treatment samples, and the expression levels of three genes are given. While the expression levels in
the control and treatment groups are not remarkably different, the variance is very
small, making the absolute value of the t-statistic very large (Feingold 2003).
Table 3.1: Calculated t-statistic from replicated study. The three genes displayed
have small within-group variability leading to inflated t-statistics.
Control
TUBA6
6.84 6.99 6.96
K-ALPHA-1 6.61 6.79 6.76
RAB31
5.76 5.88 5.73

Treatment
|t|
3.87 3.96 4.02 50.2
5.01 5.06 5.13 25.3
4.29 4.24 4.37 23.2

To address the unrealistically small variance estimates, Lönnstedt and Speed
(2002) introduce a new statistic for assessing differential expression in microarray
datasets with few replicates. Lönnstedt and Speed use an Empirical Bayes approach
that uses the data to estimate the hyperparameters and then combines the hyperparameters with statistics taken from the data in the B-statistic, which calculates the
log posterior odds of differential expression occurrence.
The expression levels for each gene i in sample j, Mij , are assumed to be independent random variables from an N (µi , σi2 ). These parameters, (µi , σi2 ), are given
conjugate priors: normal distributions for the µi and inverse gamma distributions for
the σi2 . The hyperparameters for the priors are estimated by first fixing the unknown
proportion of genes that are differentially expressed, p. Bi can then be calculated for
each gene i using an explicit formula


Bi = log 

p
1
√
1 − p 1 + nc

Ã

s2g

a + + Mg.2
2
Mg.
a + s2g + 1+nc

!v+ n2 

,

where s2g is the gene-specific sum of squares over n and Mg. is the average expression
level for each gene.
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Relative to the t-statistic, the B-statistic decreases the number of false positives
and false negatives. The B-statistic also deals with the possible inflation due to small
within-group variation and a small number of replicates.
Efron et al. (2001) propose an alternate empirical Bayes approach for detection
of differentially expressed genes and estimation of the false discovery rate. Efron et al.
assume that the observed gene expression values are a mixture of non-differentially
expressed genes and differentially expressed genes. The expression levels of nondifferentially expressed genes are characterized by density f0 ; the expression levels of
differentially expressed genes are characterized by a bimodal distribution, f1 , reflecting the genes which are either turned on or turned off. Neither of these distributions
is known; what is observed is the distribution of the scores, f , which is a mixture of
f0 and f1 , shown in Figure 3.1 as a solid line. From the mixture scores, the authors
estimate f0 and f1 and the posterior probability that a gene is differentially expressed.
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Figure 3.1: Efron’s empirically estimated densities of the null and alternative distributions from the observed mixture distribution. The observed f is the mixture of the
null f0 and the alternative f1 .

A modified t-statistic with a fudge factor, a0 , summarizes the expression values
of each gene:
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Zi =

D̄i
,
a0 + S i

where D̄i is the average of the differences in expression between sample types and
Si is the sample standard deviation for each gene i. The null distribution of Zi is
generated by permuting the sample labels. A logistic regression analysis estimates the
ratio of f0 (Z)/f (Z), where f0 (Z) is the density function of the scores for unaffected
genes and f (Z) is the mixture density. The posterior probability that a gene with
score Z is differentially expressed is calculated by

p1 (Z) = 1 − p0

f0 (Z)
,
f (Z)

where p0 is the prior probability of differential expression.
Genes with low expression levels have little variance, resulting in very large
t-statistics; the smoothing parameter, a0 , in the denominator of the scores prevents
such genes from dominating the results of the analysis. The fudge factor, a0 , is
obtained by performing the analysis for a range of values for a0 and then selecting
an optimal value. Efron suggests that the a0 value selected should find the greatest
number of differentially expressed genes.
Efron’s method is useful in that it handles high-dimensional data robustly when
sample sizes are small. Also, a full Bayesian analysis would require prior specification
of p0 , p1 , f0 , and f1 , but the authors use the structure of microarray data to estimate
an empirical version. The main weakness in Efron’s method is that instead of using
historical data to estimate p0 , p1 , f0 , and f1 a priori, the authors use the current data.
This method uses the data twice, once to estimate the priors and once to perform the
analysis using those priors.
Kendziorski et al. (2003) propose an empirical Bayes methodology to improve
the estimation of expression fold change by the use of posterior odds for the assessment of differential expression. Fold-change analysis is used to identify genes with
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expression ratios or differences between a treatment and a control that are outside of
a given cutoff or threshold. In this case, inference on each gene uses the information
about the fluctuations of expression measurements from all genes.
The authors assume that measurements which share a common mean expression level µg appear independently and identically from an observed fobs (·|µg ). Two
components of the mixture model are specified as the observed fobs (·|µg ), which characterizes fluctuations in repeated measurements from a gene having a latent expression
level µg , and a genome-wide distribution π(µg ), which represents fluctuations in these
means among genes. The authors explore two families for fobs (·|µg ). The first family
assumes gamma-distributed measurements and the second family uses log-normally
distributed measurements. A constant coefficient of variation is assumed in both
models. These models also account for differential variation in apparent fold change.
In the gamma-gamma model, the fobs (·|µg ) is a gamma distribution with mean
value µg , shape parameter α, and scale parameter λg = α/µg for measurements
z > 0.The genome-wide distribution, π(µg ), is assumed to be an inverse gamma;
fixing α, the quantity λg = α/µg has a gamma distribution with shape parameter
α0 and scale parameter v. In cases in which there are two conditions, control and
treatment, the posterior probability can be calculated by

P 1
P 2
pv0α Γ(n1 α + α0 )Γ(n2 α + α0 )( ni=1
xg,i + ni=1
yg,i + v)N α+α0
P
Pn1
,
oddsg =
2
yg,i + v)n2 α+α0
(1 − p)Γ(α0 )Γ(N α + α0 )( i=1 xg,i + v)n1 α+α0 ( ni=1

where xig and yig are the measurements from the two conditions for each gene and
N = n1 + n2 is the total number of observations on each gene g. All hyperparameters
are estimated by the data.
While this method is dependent on parametric model assumptions, the authors
suggest that the method may miss some genes, but a gene that is called differentially
expressed is most likely accurately labeled.
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Fox and Dimmic (2006) propose a two-sample t-test to determine whether or
not a gene is differentially expressed in two different samples. The proposed method
explicitly calculates the marginal distribution for the difference in the mean expression
of two samples, removing the need for point estimates of the variance that were needed
in earlier attempts to construct a t-test.
The authors assume that the likelihood of the observed data for a single gene
follows a normal distribution, dependent on the given treatment. That is, the samples
from each treatment follow a normal distribution with equal variances and possibly
different means, shown by
yi ∼ N (µ, σ 2 ),
yj ∼ N (µ + ∆µ, σ 2 ),
where i = 1, . . . , n1 and j = 1, . . . , n2 represents the number of replicates in the
control and treatment samples.
The priors on µ and ∆µ are taken to be flat. The prior probability of σ 2 follows
a scaled inverse gamma distribution with parameters ν0 and σ02 , where ν0 = 0 and σ02
is estimated by the data. The priors and likelihood are combined to give the following
posterior distribution:

n1
Y

µ

¶
1
2
√
exp − 2 (yi − µ)
p(µ, ∆µ, σ |y) ∝ p(µ, ∆µ, σ )
2
2σ
2πσ
i=1
µ
¶
n2
Y
1
1
2
√
exp − 2 (yj − (µ + ∆µ)) ,
×
2σ
2πσ 2
j=1
2

2

1

where n1 and n2 are the number of measurements in each sample. The use of the
authors’ assumptions and definitions causes the marginal posterior distribution of ∆µ
to follow a t-distribution. That is,
∆µ − ∆ȳ
|Θ ∼ tνn ,
σn sqrt n11 + n12
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where νn = n1 + n2 − 2 and νn σn2 = ν0 σ02 + (n1 − 1)s21 + (n2 − 1)s22 . A hypothesis test
is then performed by asserting the null hypothesis that there is no true difference in
expression levels, ∆µ = 0. When the posterior probability of having no differential
expression, P(∆µ = 0|y), approaches zero, the null is rejected and the gene is called
differentially expressed.

3.2

Hierarchical Models
Gottardo et al. (2003) present a hierarchical Bayesian model with independent

Gaussian modelling that addresses the two main issues in microarray studies: the
small number of replicates and the large number of genes. This model gives rise to
four statistics that are useful in different situations.
The first statistic is based on the situation in which there is only treatment
data available. The statistic is calculated as follows, where ν0 , τ0 , νa and τa are the
hyperparameters of the inverse gamma priors for the variances of the genes that are
not differentially expressed, ν0 and τ0 , and the genes that are differentially expressed,
νa and τa .
B1 =
where Sg2 =

Ã

1 − p √ Γ(νa )Γ(ν0 + n2 /2) τ0ν0 (τa + n22−1 Sg2 )νa +n2 /2
2
1+
2 ν0 +n2 /2
p
Γ(ν0 )Γ(νa + n2 /2) τaνa (τ0 + n22 Sg0
)

Pn2

2
2
i=1 (Ygi − Ȳg ) /(n2 − 1) and Sg0 =

Pn2

2
i=1 (Ygi − 0) /(n2 ).

!−1

,

The B1 statistic

is found to be more powerful than the B-statistic calculated by Lönnstedt and Speed
(2002) through simulation studies when the sample size is less than 5. When sample
size increases, the variations of the B-statistic are comparable.
The second statistic is used when both control and treatment data are available
for each gene; therefore, the analysis is treated as a two-sample problem to determine
if there is a difference in mean expression. The calculation of B2 is essentially the
same as the calculation of B1 , with functions of hyperparameters and the expected
proportion of differentially expressed genes. The major difference is in the estimates
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of the variability of gene expression: in B2 the numerator variability estimate is
equivalent to a two-sample pooled s2 , and the denominator is also a pooled estimate
of s2 , using a weighted average of the mean from both samples.
A change in the variance of the expression ratios can be attributed to a biological event. Therefore, a third statistic is used to test for a difference in the variance
of the expression levels between the control and treatment conditions. The principal difference between calculating B2 and B3 is that both the numerator and the
denominator include the different functions of the same estimates of gene expression
variability for the control and treatment data.
The fourth statistic detects a given gene with different mean ratios and/or
different variances in the control and treatment groups. Primarily, B4 calculation
differs from B3 calculation by using a pooled variance in the denominator, as in B2 .
Gottardo et al. compare B1 and B2 to many equivalent statistics and find the
B-statistics to be superior in finding correctly differentially expressed genes. There
are no current statistics that relate to B3 and B4 . Lönnstedt and Speed’s B-statistic
assumes a normal likelihood for the data with normal and inverse gamma priors for
the means and variances, respectively. Gottardo’s B-statistics account for another
level of uncertainty by including normal priors on the mean of the gene expression
means and including gamma priors on the parameters of the inverse gamma prior on
the variances.
In order to build a suitable parametric model to allow for comparison of normal
and tumor tissues and to characterize the behavior of the genes in each group, Ibrahim
et al. (2002) develop a class of models with hierarchical priors for the parameters that
allow for correlation between the genes.
The expression level for a given gene, xjig , can be described by a mixture random
variable with a discrete and a continuous component if j = 1, 2 indexes the tissue
type, normal vs cancer, and xjig is the mixture random variable for the jth tissue
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type for the ith individual, i = 1, 2, ..., nj , and the gth gene, g = 1, 2, ..., G. The
discrete portion is a point mass at some c0 , a threshold value assumed to be the
level of expression at which a gene is not differentially expressed. The continuous
component, y, is the expression level of the gene and is lognormally distributed. The
observed gene expression can be written as



c 0
with probability p
xjig =


c0 + y with probability 1 − p,

letting δjig = I(xjig = c0 ) and pjg = P (δjig = 1). The likelihood function based on

the data, D, is given by

2

L(µ, σ , p|D) =

nj G
2 Y
Y
Y
j=1 i=1 g=1

δ

2 1−δjig
)
.
pjgjig (1 − pjg )1−δjig p(yjig |µjg , σjg

Ibrahim et al. then compute the posterior distribution for each gene of ξg =
ψ2g /ψ1g , where
ψjg

2
σjg
= c0 pjg + (1 − pjg ) c0 + exp µjg +
2

µ

¶

.

As in many other Bayesian microarray analyses, Ibrahim et al. (2002) spec2
ify a hierarchical prior for µjg as being independent N (µj0 , τ0 σjg
/n̄j ), where n̄j =
P
P
nj
G
1
i=1 δjig ) and τ0 > 0 is a defined scalar. The µj0 have a prior of
g=1 (nj −
G

2
2
N (mj0 , νj0
). For σjg
, the priors are independent inverse gamma with hyperparame-

ters (aj0 , bj0 ). There is also a gamma prior put on bj0 with hyperparameters (qj0 , tj0 ),
which allow prior correlation between the genes. Finally, pjg is transformed to ejg by
p

taking the log( 1−pjgjg ). For these values of ejg , a normal prior is designated with mean
2
2
µj0 and variance kj0 wj0
, where µj0 is distributed as N (µ̂j0 , hj0 wj0
) and kj0 , hj0 , and
2
wj0
, are the specified hyperparameters. These hyperparameters can either be defined

by historical data or expert opinion; if neither is available, Ibrahim and Chen provide
some guide values.
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Ibrahim and Chen’s model is very similar to Kendziorski et al. (2003), with the
exception of the prior structure. This approach provides more flexibility for making
inferences about the differential expression of genes than other types of clustering
algorithms. It distinguishes the pattern of gene expression in the two types of tissue,
and can easily be extended to more than two tissue types.
The Bayesian models discussed previously are useful for the analysis of any
experiment because of their integration of many levels of uncertainty and because
of their possible resolution of the difficulties inherent in microarray data. Bayesian
models are also useful when data includes many levels of replication. Oftentimes,
many independent, but not necessarily identical, studies are conducted in order to
understand a certain biological process. Conlon et al. (2006) introduce a framework
for incorporating data from multiple independent microarray experiments with several
sources of replication. This framework includes a hierarchical Bayesian model that
takes into account each gene on each slide from each experiment.
Conlon et al. (2006) assume that there are only two conditions present in each independent experiment, control and treatment, and that each experiment is conducted
using the same assay platform. The model that produces the posterior probability
that a gene is differentially expressed based on gene expression levels across j = 1, ..., J
independent studies is presented in Figure 3.2, where yjges is the log-expression ratio
for gene g in experiment e on slide s. The average expression over all slides within
experiment e of study j is given by µjge . The log-expression ratio for each gene of
study j is given by θjg . There is also an indicator function, Ig , for differential expression of gene g, where p is the percent of differentially expressed genes. The percent
of differentially expressed genes, p, has a uniform prior distribution. The posterior
distributions for each parameter are simulated using MCMC methods. Finally, the
posterior probability, Dg , is calculated for gene g across all studies.
Conlon et al. (2006) use the False Discovery Rate (FDR) defined by Benjamini
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yjges |µjge

∼

2
N (µjge , τjg
)

µjge |θjg

∼

2
N (θjg , σjg
)

θjg |Ig = 0

∼

2
N (0, ηjg0
)

θjg |Ig = 1

∼

2
N (0, cj × ηjg0
)

2
ηjg0

∼

as21
χ2a

cj

∼

bs22
χ2b

Ig

∼

Bernoulli(p)

p

∼

Uniform(0, 1)

Figure 3.2: Hierarchical model for the probability that a gene is differentially expressed based on gene expression levels across j = 1, ..., J independent studies.

and Hochberg (1995) and the Integration-driven Discovery Rate (IDR) defined by
Choi et al. (2003) to evaluate the proposed model. The FDR is the number of
false discoveries made divided by the total number of discoveries. The IDR is the
number of genes discovered in a meta-analysis that were not discovered in any of
the individual studies alone divided by the total number of discoveries. Essentially,
the IDR quantifies the gain of information by pooling individual experiments. These
studies showed that by using this heirarchical model for pooling data, there was a
considerable increase in the IDR for multiple values of γ, while FDR is consistently
low; more truly differentially expressed genes were ascertained with a smaller chance
of false positives with this model as compared to the individual studies.
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4. CASE STUDY

4.1

Tamoxifen and Breast Cancer
This work examines an experiment performed to determine the preferential

regulation of genes by tamoxifen in breast cancer cells (Frasor et al. 2006). Estrogens
act on target tissues by binding to estrogen receptors. An estrogen receptor is a
protein molecule found inside cells that are targets for estrogen action. Estrogen
receptors, located in the cell nucleus, contain a site to which only estrogens or closely
related molecules can bind. In the absence of estrogen molecules, these estrogen
receptors are inactive and have no influence on DNA, but when an estrogen molecule
enters a cell and passes into the nucleus the estrogen binds to its receptor and causes
the shape of the receptor to change (Parker et al. 1997). This estrogen-receptor
complex then binds to specific DNA sites. After the complex binds to the DNA sites,
nearby genes become active. The active genes produce molecules of mRNA, which
give rise to specific proteins that influence the function of the cell (Hayashi et al.
2003). Estrogen is important in programming the body for sexual reproduction,
controlling cholesterol production, and preserving bone strength. Estrogen can also
have a deleterious effect on health by advancing the production of epithelial cells
in the breast. Although the ability to stimulate cell production is one of estrogen’s
normal roles, it can also increase a woman’s chance of developing breast cancer (Clark
et al. 1998).
Although estrogen does not appear to directly cause the DNA mutations that
trigger the development of human cancer, estrogen does stimulate cell production. If
one or more breast cells already possesses a DNA mutation that increases the risk
of developing cancer, these cells, along with normal epithelial cells, will reproduce
in response to estrogen stimulation. Thus, estrogen-induced cell production leads to
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an increase in the total number of mutant cells that exist. These cells have an increased risk of becoming cancerous, so the chance that cancer may develop is increased
(Parker et al. 1997). Some drugs that block the action of estrogen in certain tissues
can mimic the action of estrogen in other tissues. Differences in chemical structure
allow estrogen-like drugs to interact with the estrogen receptors of different tissues.
Tamoxifen blocks the action of estrogen in breast tissue by binding to the estrogen
receptors of epithelial cells (Swain 2001). The experiment to be investigated assesses
an estrogen receptor α (ERα) positive breast cancer cell line (MCF-7) infected with
adenovirus-ERβ and treated with tamoxifen. The cells were infected with adenovirus
carrying either estrogen receptor β (AdERβ) or no insert (Ad), and treated with
trans-hydroxytamoxifen (TOT). The results provide insight into tamoxifen activity
in the presence of both ERα and ERβ, which illuminates the potential therapeutic
and diagnostic implications of tamoxifen with regard to breast cancer.

4.2

Data Analysis
In a typical microarray experiment, RNA obtained under various conditions

(patients, treatments, disease states, etc.) is hybridized to microarrays. By tagging
the RNA with a fluorescent marker, intensity values can be obtained that correspond
to the amount of labeled RNA bound to the array. On the widely used Affymetrix
platform, gene expression is measured using probe sets consisting of 11 to 20 perfect
match (PM) probes of 25 nucleotides, which are complementary to a target sequence,
and a similar number of mismatch (MM) probes in which the 13th nucleotide has
been changed. The MM probe measurements are thought to comprise most of the
background cross-hybridization and stray signals affecting the PM probes (Affymetrix
1992). The tamoxifen experiment is conducted using Affymetrix chips.
In performing an exploratory analysis of the six data samples, boxplots of the
probe intensities for each chip are created (see Figure 4.1). The box plots of inten25

sities from all arrays should have a similar mean and range. The first sample of the
treatment data may be different from the other two samples. This must be corrected
for in order to find differences in expression levels due to biological effects rather than
slightly different samples. The samples are skewed because the measurements are
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Figure 4.1: Boxplots of the data before normalization; the three control (Ad) replicates are on the left and the three treatment (AdERb) replicates are on the right.

To explore the dependence of the variance of the signal intensities on the
strength of the signal, an MVA plot of a pair of chips is examined or the average
signals of treatment groups are examined (Heber and Sick 2006). Figure 4.2 is a
scatter plot of the average log differences of a pair of chips versus the average mean
of their log signals. The MVA plots comparing sample chips within the control do
not have any significant abnormalities. There are some problems with the MVA plots
comparing the treatment sample chips, as seen in Figure 4.2; while the MVA plots
should be linear, this plot has noticable curvature.
To conduct a chip-to-chip analysis, the data must be standardized. The normalization corrects for systematic differences within slides or between slides that do
not represent true biological variation between samples.
To normalize the data, a method called IdealMM is used (Bolstad 2001). This
approach compares the mismatch and perfect match probe intensities. The quantile
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Figure 4.2: MVA plot of two chips within the treatment sample before normalization,
where A is the x-axis and M is the y-axis.

normalization method is used to correct for the differences in the distributions of intensities of the chips. This method gives all the chips the same empirical distribution.
Finally, the median-polish summary method is used; this method fits a multi-chip linear model to the data from each probe set. The boxplots in Figure 4.3 show that the
post-standardization probe intensities are less variable and have a constant median
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Figure 4.3: Boxplots of the data after normalization; the three control replicates are
on the left and the three treatment replicates are on the right.

The normalization process also removes the curvature and other problems in
the MVA plots within the treatment samples. The post-normalization MVA plot in
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Figure 4.4 displays the same samples observed in Figure 4.2, but no curvature is
apparent.

Figure 4.4: MVA plot of two chips within the treatment sample after normalization,
where A is the x-axis and M is the y-axis.

The Bayesian t-test proposed by Fox and Dimmic (2006) is performed to determine which genes are differentially expressed using non-informative priors. That
is, the mean and the difference in means are given flat priors and the variance prior
parameters are estimated by the data. The choice of likelihood and prior distributions results in the marginal posterior distribution of the difference, ∆µ, following a
t-distribution.
Using the marginal posterior distribution of ∆µ, the t-statistic (see section 3.1)
is calculated to determine differential expression. The model is simplistic but effective
in finding genes with a high probability of differential expression. The authors use a
cutoff p-value of 0.05 to indicate differential expression. Using this bound, more than
3,700 genes are called significant. The top 10 genes and the corresponding t-statistics
and p-values are shown in Table 4.1.
Figure 4.5 gives a plot of the difference in mean expression for each gene versus
the p-value. From this figure, the genes with large differences have low p-values. The
dotted line represents the cutoff p-value to indicate differential expression; in this
case, the line is the bound 0.05.
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Table 4.1: List of the top 10 genes and their corresponding t-statistics and P -values.
t-statistic
-38.96389
38.00555
-38.19704
-29.35590
-27.15826
-25.81545
25.10982
-24.61897
21.92268
-21.69021
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p-value
< 10e-16
< 10e-16
< 10e-16
< 10e-16
< 10e-16
1.110223e-16
1.110223e-16
2.220446e-16
1.887379e-15
2.331468e-15
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Figure 4.5: Plot of the difference in means versus p-values. The horizontal line
represents the 0.05 cutoff p-value indicating differential expression.

The analysis of the data using flat priors for the mean and difference in means
and data-driven hyperparameters for the prior on the variance is useful. However,
there are many sources of information about the genome that should be incorporated
into the analysis.
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4.3

Types of Prior Information Available
The gene expression community shares the data collected from experiments

through online databases. As a national resource for molecular biology information,
the National Center for Biotechnology Information (NCBI) website creates literature,
journal, and nucleotide databases for public access and develops tools and software
for database mining and data analysis. As of May 1, 2007, Gene Expression Omnibus
(GEO) had catalogued more than 150,000 microarray studies (National Center for
Biotechnology Information 2002a); the Stanford MicroArray Database had details on
over 13,000 experiments (Stanford University 2003); and SAGEMAP included over
600 libraries with tissue and cell information on more than 15 organisms (National
Cancer Institute 1996).
PubMed is a database which holds articles from medical and health-related
journals. As of May 1, 2007, there were more than 14,500 articles including the
keywords breast cancer and estrogen receptors (National Center for Biotechnology
Information 2002b). By inputting these keywords and a specific gene name, more
than 350 articles were returned.
The gene Estrogen Receptor 2, or ER beta, is one gene involved in the tamoxifen experiment. As of May 1, 2007, the PubMed library had more than 14,500
articles containing information about Estrogen Receptor 2 and estrogen receptorrelated breast cancer (National Center for Biotechnology Information 2002b). The
first few articles are cited in Table 4.2. As of May 1, 2007, the Gene Expression
Omnibus contained twenty breast cancer experiments involving the gene ER beta,
all of which are shown in Table 4.3 (National Center for Biotechnology Information
2002a). One paper presents two separate experiments (Coser et al. 2003), and another
paper provides a series of three experiments (Wu et al. 2006). The bolded experiment
represents the Tamoxifen experiment examined in this thesis.
Four of the 20 breast cancer experiments found in GEO are very similar to the
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Table 4.2: Five of the 14,500 estrogen receptor breast cancer articles mentioning ER
beta, as of May 1, 2007.
Author
Brama et al. (2007)

Experiment
Osteoblast-conditioned medium promotes proliferation
and sensitizes breast cancer cells to imatinib treatment.
Eakin et al. (2007)
Estrogen receptor α is a putative substrate
for the BRCA1 ubiquitin ligase.
Marx et al. (2007)
Proteasome Regulated ERBB2 and Estrogen
Receptor Pathways in Breast Cancer.
Poola and Yue (2007) Estrogen receptor alpha (ERα) mRNA copy numbers
in immunohistochemically positive-, and negative breast
cancer tissues.
Ray et al. (2007)
Diet-induced obesity and mammary tumor development
in relation to estrogen receptor status.

motivating experiment. The first experiment deals with the analysis of the response of
estrogen receptor (ER) negative breast cancer cells infected with full-length ER alpha
adenoviral constructs to treatment with 17beta-estradiol (E2) (Moggs et al. 2005).
The results of this experiment provide insight into the anti-proliferative effect of E2 on
breast cancer cells reexpressing ER (see Table 4.4). The second experiment explores
the expression profiling of estrogen receptor positive breast cancer cell lines treated
with estradiol for 24 hours. MCF-7, T47-D, and BT-474 breast cancer cell lines are
examined (Rae et al. 2005). The results identify candidate genes involved in estrogenstimulated breast cancer growth (see Table 4.5). The third experiment studies the
analysis of tumors from 49 breast cancer patients (Farmer et al. 2005). Tumors are
classified into a luminal, basal, or novel molecular apocrine class. Apocrine tumors
are estrogen receptor negative (ER-) and androgen receptor positive (AR+), while
luminal tumors are ER+ and AR+, and basal tumors are ER- and AR-. Summary
statistics for gene expression levels are shown in Table 4.6. The fourth experiment
is the analysis of estrogen receptor (ER) alpha positive MCF-7 breast cancer cells
overexpressing constitutively active c-erbB-2. Results indicate that increased MAPK

31

activation results in loss of ER-alpha expression (see Table 4.7). These four experiments target estrogen receptor breast cancer. The ten excluded experiments either
examine estrogen receptors in cancers of other parts of the body or involve breast
cancer but not with respect to estrogen receptors.
Instead of the flat priors and data-driven hyperparameters used in the previous
analysis, information from these experiments are used to build informative priors.
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Table 4.3: The twenty breast cancer experiments involving ER beta, as of May 1,
2007.
Author
Coser et al. (2003) (2)

Experiment
Global analysis of ligand sensitivity of estrogen inducible
and suppressible genes in MCF7/BUS breast cancer
cells by DNA microarray.
Wu et al. (2003)
DACH1 inhibits transforming growth factor-beta
signaling through binding Smad4.
Acevedo et al. (2004)
Selective recognition of distinct classes of coactivators
by a ligand-inducible activation domain.
Mecham et al. (2004)
Sequence-matched probes produce increased
cross-platform consistency and more reproducible biological
results in microarray-based gene expression measurements.
Stitziel et al. (2004)
Membrane-associated and secreted genes in breast cancer.
Chen et al. (2005)
Identification of transcriptional targets of HOXA5.
Farmer et al. (2005)
Identification of molecular apocrine breast tumours
by microarray analysis.
Itoh et al. (2005)
etrozole-, anastrozole-, and tamoxifen-responsive genes in
MCF-7aro cells: a microarray approach.
Moggs et al. (2005)
Anti-proliferative effect of estrogen in breast cancer cells
that re-express ERalpha is mediated by aberrant regulation
of cell cycle genes.
Poola et al. (2005)
Identification of MMP-1 as a putative breast cancer
predictive marker by global gene expression analysis.
Rae et al. (2005)
GREB 1 is a critical regulator of hormone dependent
breast cancer growth.
Wonsey and Follettie (2005) Loss of the forkhead transcription factor FoxM1 causes
centrosome amplification and mitotic catastrophe.
Creighton et al. (2006)
Activation of mitogen-activated protein kinase in
estrogen receptor alpha-positive breast cancer cells in vitro
induces an in vivo molecular phenotype of estrogen receptor
alpha-negative human breast tumors.
Dittmer et al. (2006)
Parathyroid hormone-related protein regulates
tumor-relevant genes in breast cancer cells.
Frasor et al. (2006)
Gene expression preferentially regulated by
Tamoxifen in breast cancer cells and correlations
with clinical outcome.
Richardson et al. (2006)
X chromosomal abnormalities in basal-like
human breast cancer.
Wu et al. (2006)
Glucocorticoid receptor activation signals through forkhead
transcription factor 3a in breast cancer cells
(Series 1, 2, 3).
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Table 4.4: Expression values for Estrogen Receptor 2 (ER beta) in breast cancer cells
reexpressing estrogen receptor alpha response to 17beta-estradiol. The expression
values for Estrogen Receptor 2 (ER beta) in the analysis of the response of estrogen
receptor (ER) negative breast cancer cells infected with full-length ERα adenoviral
constructs to treatment with 17beta-estradiol (E2).
Sample
AdlacZ+est

Expression Level
68.5
15.7
97.3
AdERa+est 189
174
107

Table 4.5: Expression values for Estrogen Receptor 2 (ER beta) in the estrogen effect
on estrogen receptor alpha positive breast cancer cell lines. The expression values for
Estrogen Receptor 2 (ER beta) in estrogen receptor positive breast cancer cell lines
treated with estradiol for 24 hours. MCF-7, T47-D, and BT-474 breast cancer cell
lines examined.
Sample
Control
MCF-7
T47-D
BT-474
Est. Treated
MCF-7
T47-D
BT-474
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Expression Level
6.16
6.22
5.80
5.87
5.92
5.71
6.23
6.27
5.89
5.86
5.87
5.98

Table 4.6: Expression values for Estrogen Receptor 2 (ER beta) in molecular apocrine
breast tumors. Analysis of tumors of 49 breast cancer patients. Tumors classified into
a luminal, basal, or novel molecular apocrine class. Apocrine tumors are estrogen
receptor negative (ER-) and androgen receptor positive (AR+), while luminal tumors
are ER+ and AR+, and basal tumors are ER- and AR-.
Sample
Expression Level
Apocrine Tumor (n = 6) 6.442 (0.0054)
Basal Tumor (n = 16)
6.467 (0.0077)
Luminal Tumor (n = 27) 6.325 (0.354)

Table 4.7: Expression values for Estrogen Receptor 2 (ER beta) in ER α positive
breast cancer cells response to hyperactivation of MAPK pathway. The expression
values for Estrogen Receptor 2 (ER beta) in ER alpha positive MCF-7 breast cancer
cells overexpressing constitutively active c-erbB-2.
Sample Expression Level
Control 5.896
6.016
5.894
erbB-2 6.022
6.005
6.014
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5. METHODS

Scientists are rigorously honest about reporting experiment results and how
those results are obtained in formal publications. The National Academy of Sciences’
report on the responsibilities of authorship in Biological Life Sciences (National Research Council 2003) explain that scientists have an ethical duty to allow free and
open access to supporting data. Most scientists agree with this principle because
results that cannot be replicated are suspect. This open access to data allows scientists to create models that reflect an increase in genomic knowledge; this increase in
knowledge is often disregarded.

5.1

Combining Information Across Studies
Most Bayesian methods for the study of microarray analysis use vague priors

or priors with data-driven hyperparameters. Given the vast amount of genomic information available, stronger priors may be constructed. However, the number of genes
involved, the variety of gene expression platforms, and the thousands of experiments
documented pose some difficulties in building informative priors.
Combining information across multiple studies is challenging. In the case of
microarray studies, the expression levels of the same genes have been measured on
different array platforms. In addition, technical and biological variability generally
lead to measurements of gene expression that may not be comparable across studies.
There are few methods that deal with these complications.
To avoid dealing directly with measurements of gene expression that may not
be comparable, several approaches have been proposed. Rhodes et al. (2002) compute q-values (Benjamini and Hochberg 1995) for each gene and define a differential
expression signature for each experiment as the set of genes with q-values below a
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pre-defined threshold. The meta-signature is declared to be all genes present in at
least J signatures, where J is selected by permutation testing.
In another effort to combine information across studies, Parmigiani et al. (2004)
use information on the correlation between gene expression measurements. Rather
than providing an aggregate inference, this approach focuses on identifying a set of
comparable genes, namely genes for which the correlation of expression values among
other genes in the array was similar across studies. This procedure evaluates gene
expression consistencies across platforms rather than pooling gene expression values.
This method identified genes with reproducible expression patterns across studies and
improved correlation across studies.
Gene expression data generated with different microarray platforms are not
directly comparable; even within the same platform different protocols for sample
preparation, array hybridization, and data analysis can result in variation among
datasets. Because the composition of microarrays is regularly updated to incorporate
new genes with improved target sequences, it is difficult to combine data from different
generations of the same microarray platform. Despite this difficulty, Yuen et al.
(2002) compare microarray measurements between Affymetrix GeneChips and twocolor cDNA microarrays and find that, although the fold changes of differentially
expressed genes showed poor correlation across array platforms, the rank orders of
differentially expressed genes are comparable.
In light of the information accumulating about the genome and the ability to
combine information across studies, it seems reasonable to believe there is some prior
knowledge about the probability that a specific gene will be differentially expressed
in a new experiment. Public databases can be queried to obtain information about
the expression levels of a gene in different types of tissues. This information can be
combined into an informative prior on the probability of differential expression.
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5.2

Model Specifications
A two-sample Bayesian t-test will determine if there is a difference in expression

between the cells infected with adenovirus carrying either AdERβ or Ad. This test is
based on the model used in Fox and Dimmic (2006). The likelihood of the observed
data in sample i for a single gene g follows a normal distribution depending on the
treatment group. That is,
yig ∼ N (µg , σ 2 ) and
yig ∼ N (µg + ∆g , σ 2 ),
where ∆g reflects the difference in expression between the treatment groups.
Four sets of priors are explored in this work. First, of the relevant historical
studies researched, one of the experiments that is similar to the tamoxifen experiment
is used to give estimates for the conjugate prior distributions. We assume normal
priors for the mean of each gene, µg , normal priors for ∆g , and inverse gamma priors
for σ 2 .
A second set of priors applies the power prior approach introduced by Ibrahim
and Chen (2000). Each historical experiment has a likelihood that is assumed to
follow an N (θg , τ 2 ) distribution. The initial priors for µg , ∆g , and σ 2 are taken to be
N (µ0 , σ 2 /λ0 ), N (0, σ 2 /λ0 ) and IG(ν0 , σ02 ), respectively. Each a0k has an independent
beta distribution with parameters (ak , bk ), where k = 1, . . . , L0 . The formula shown
in section 2.3.1 gives a joint power prior for (µg , ∆g , σ 2 , a0 ).
The third set of priors uses an empirical Bayes approach to estimate the parameters of the prior distribution on the three parameters, µg , ∆g , and σ 2 .
The fourth set of priors uses an empirical Bayes approach to estimate the parameters of the prior distribution on the variance and assumes flat priors on the mean
and difference in means. That is, the joint prior is assumed to be proportional to the
inverse gamma prior on the variance with data-driven hyperparameters. The prior
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distributions lead to the following posterior distribution
n1
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where n1 and n2 are the number of measurements in each sample. The marginal
posterior for ∆g can be found and used in a hypothesis test of differential expression.
The null hypothesis assumes that the true difference in expression levels is zero;
that is, ∆g = 0 or some other threshold degree. When the posterior probability of
no differential expression, P r(∆g = 0|y), is less than a cutoff value α∗ , the null is
rejected and the gene is called differentially expressed.
5.3

Perl Script
A Perl script obtains the hyperparameters of the priors for one gene. The

script has to search for a full list of previous experiments involving the gene, choose
the relevant experiments, and extract information from these experiments to specify
the hyperparameters of the prior distributions.
The script accesses the GEO database to search for experiments involving estrogen receptors, breast cancer, and the given gene. The resulting list includes a
summary of each experiment, as seen in Figure 5.1. The relevant experiments are
chosen by searching the experiment summary, the ”Experiment” field in Figure 5.1,
for both breast cancer and estrogen receptors. The experiments that are not chosen
may examine estrogen receptors in cancers of other parts of the body or involve breast
cancer but not with respect to estrogen receptors.
The data set from each of the relevant studies is split into two groups. The
web page includes check-boxes that correspond to a specific group of samples. These
check-boxes are shown in Figure 5.2 in the ”4 assigned subsets” table under the
heading ”Samples”. The subsets may split the samples according to the treatment
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Figure 5.1: List of experiments for one gene from GEO. The Perl script searches the
Experiment field for both breast cancer and estrogen receptors to identify the relevant
experiments (National Center for Biotechnology Information 2002a).

or by some facet of the tissues. To extract the groups of samples, the HTML source
code is searched for the check-box code, and the subset of samples is retrieved from
this portion of the HTML code. The script exports the groups of sample numbers to
a text file.
The script prints out the labels of the subsets of each data set. The user chooses
two of the labels that split the data into two subsets. The files corresponding to the
two groups specified by the user are imported. For each sample number within each
file, the script retrieves the webpage that includes the table of expression values for
all genes in the sample, as seen in Figure 5.3. The gene name is located and the
script keeps all information between the gene name and the next gene number. The
expression value is extracted from this information, stored in an array, and written
to a text file. These files are read into R for further analysis.
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(a) All samples

(b) Subset of samples

Figure 5.2: Possible subsets of samples marked by check-boxes. In (a), all samples
are marked by a check. In (b), the subset of samples marked by the first check-box
are now un-checked (National Center for Biotechnology Information 2002a).

41

Figure 5.3: Table of expression values of all genes for one sample.
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6. DATA ANALYSIS

The method described in the previous chapter is applied to 10 of the 22,283
genes in the data set. For ease of explanation, the ten genes are given numbers,
as shown in Table 6.1. The first five of the genes are randomly chosen from those
genes that are differentially expressed, the next two are from the list of genes that
are equivalently expressed, and the last three are from the list of genes that are
moderately expressed.
Table 6.1: Genes to which the proposed method is applied. These genes are selected
from the case study analysis; five from the list of differentially expressed genes, three
just beyond the cutoff p-value, and two non-significant genes.
Group
Differentially Expressed

Equivalently Expressed
Moderately Expressed

Reference Number Gene Reference Number
Gene 1
211120 x at
Gene 2
218039 at
Gene 3
200974 at
Gene 4
202240 at
Gene 5
61732 r at
Gene 6
213570 at
Gene 7
204773 at
Gene 8
91952 at
Gene 9
202378 s at
Gene 10
31799 at

Table 6.2 gives the four experiments that are returned for all ten genes. This is
not a requirement of the script, but a feature of the data. After further investigation
of the five data sets, it is determined that all five experiments involve the same genes.
The only exceptions are the control genes.
Gene 1 has a very high probability of differential expression. The Perl script
is run for Gene 1. The script brings back the list of ways to split the data for four
experiments. The control and treatment groups are entered for each experiment. The
eight text files with the arrays of gene expression values are imported into R. The two43

Table 6.2: The four breast cancer experiments mined by the Perl script. These four
experiments are used in the analysis of all ten genes.
Author
Farmer et al. (2005)

Experiment
Identification of molecular apocrine breast tumours
by microarray analysis.
Moggs et al. (2005)
Anti-proliferative effect of estrogen in breast cancer cells
that re-express ERalpha is mediated by aberrant regulation
of cell cycle genes.
Rae et al. (2005)
GREB 1 is a critical regulator of hormone dependent
breast cancer growth.
Creighton et al. (2006) Activation of mitogen-activated protein kinase in
estrogen receptor alpha-positive breast cancer cells in vitro
induces an in vivo molecular phenotype of estrogen receptor
alpha-negative human breast tumors.

sample t-test model is run four times: once with the power prior distribution using all
four previous experiments, ”Power Prior,” once using the first experiment to estimate
the hyperparameters of the prior distributions, ”Informative Prior,” once using the
tamoxifen data to estimate the hyperparameters of the prior distributions, ”Empirical
Prior,” and once with the joint prior proportional to the prior for the variance with
data-driven hyperparameters, ”Flat Priors”. Figure 6.1 gives a plot of the marginal
posterior distribution for ∆g using all four priors. The use of the flat priors on the
mean and difference in means and the data-driven hyperparameters of the variance
prior and the empirically estimated prior give nearly identical posterior distributions.
The spread of these distributions is roughly 40 gene expression units. The power prior,
the empirical prior, and the flat priors have posteriors centered at values greater than
zero, but they are not as extreme as the posterior of the informative prior. The
previous study chosen is one in which Gene 1 has a large probability of differential
expression (Moggs et al. 2005). The spread of the posterior distributions decreases
as the amount of information in the prior increases; that is, the power prior gives a
posterior with about half the spread of the posterior using the empirically estimated
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prior. The choice of prior distributions also affects the estimated means, as seen in
Table 6.3. The P(∆g > 0) is approximately the same for all four priors.
One common concern about the Bayesian approach to microarray analysis is
that prior distributions are not objective. In this case, the choice of priors used does
not affect the outcome; namely, Gene 1 is called differentially expressed regardless
of the prior distribution. This outcome is expected, as the prior distribution should
matter in cases where the difference in expression levels is near, but not equal to zero.

Figure 6.1: Marginal posterior distribution of ∆g for Gene 1 using four different priors.
The power prior has the smallest spread and the empirical prior and flat priors have
the largest spread. The informative prior has a spread in between the non-informative
priors and power prior and a mean shifted up about 100 gene expression units.

Table 6.3: Expected value of ∆g and P(∆g > 0) for Gene 1 using four different
priors. The P(∆g > 0) is approximately the same using any of the prior distributions,
regardless of the large differences in the expected values.
Prior Distribution
Informative Prior
Power Prior
Empirical Prior
Flat Priors

E(∆g ) P(∆g > 0)
99.48
> 0.999
2.357
0.996
9.547
> 0.999
9.695
> 0.999
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Gene 2 also has a high probability of differential expression. The Perl script
brings back the list of ways to split the data for the same four experiments as were used
for Gene 1. The control and treatment groups chosen are the same as in Gene 1. The
same experiment is used to estimate the hyperparameters for the informative prior.
The two-sample t-test model is run four times. Figure 6.2 gives a plot of the marginal
posterior distribution for ∆g using the four priors. The four posterior distributions
are roughly centered around zero, though the flat priors pull the posterior slightly to
the left. As with Gene 1, the spread of the distributions increases as the amount of
knowledge included decreases, with the exception of the empirical prior and the flat
priors. The expected value of ∆g is shown in Table 6.4 using the four priors. The
expected values and P(∆g > 0) are affected by the four priors.

Figure 6.2: Marginal posterior distribution of ∆g for Gene 2 using four different
priors. The power prior has the smallest spread and the empirical prior has the
largest spread. The informative and flat priors give posteriors with roughly the same
spread.

Gene 3, Gene 4, and Gene 5 are three other differentially expressed genes with
approximately the same difference in means. An experiment performed by Moggs
et al. (2005) is used to estimate the hyperparameters for the informative prior. The
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Table 6.4: Expected value of ∆g and P(∆g > 0) for Gene 2 using four different priors.
The use of the four priors has a noticeable effect on both the expected values and the
P(∆g > 0).
Prior Distribution
Informative Prior
Power Prior
Empirical Prior
Flat Priors

E(∆g ) P(∆g > 0)
-2.174
0.431
-2.026
0.267
-4.508
0.488
-3.861
0.498

marginal posterior distributions using the four priors of ∆g for Gene 3, Gene 4 and
Gene 5 are shown in Figure 6.3. The marginal posteriors for Gene 3 using the the
empirical prior and the flat priors are equivalent. The distributions are centered
roughly around zero and the spread increases as the amount of information in the
prior decreases. The marginal posteriors of Gene 4 using the empirical and power
prior look equivalent to those in Gene 3. The flat priors give a marginal posterior for
Gene 4 that is barely shifted to the right. The posterior using the informative prior is
shifted down about 40 gene expression units due to the differential expression of the
gene in the previous experiment. The posteriors for Gene 5 are close to those in Gene
3 with the exception of the informative prior. The informative prior gives a posterior
that is shifted down about 15 gene expression units. The four prior distributions
change the expected values and P(∆g > 0), as shown in Table 6.5.
Gene 4 and Gene 5 are only called differentially expressed using the informative
prior. Figure 6.4 gives a plot of the power, informative and empirical priors for both
Gene 4 and Gene 5. The empirical prior and the flat priors give equivalent posteriors
for all three genes. The power prior has the smallest spread, the empirical prior and
flat priors have the largest spread and the informative prior has a spread in between
the non-informative priors and the power prior. The informative prior is shifted to
the left for both Gene 4 and Gene 5.
The informative prior uses one historical experiment to estimate the prior pa47

Figure 6.3: Marginal posterior distribution of ∆g for Gene 3, Gene 4, and Gene 5
using four different priors. The empirical prior and the flat priors give equivalent
posteriors for all three genes. The power prior has the smallest spread, the empirical
prior and flat priors have the largest spread, and the informative prior has a spread
in between the non-informative priors and the power prior. The informative prior is
shifted to the left for both Gene 4 and Gene 5.
rameters. The choice of experiment can radically change the prior and, consequently,
the posterior. Table 6.6 shows the estimated value of ∆0 for each of the four previous
experiments for Gene 4 and Gene 5. Experiment 3, the strongest historical evidence
of differential expression, is used in this analysis. Suppose the expert believed that
Experiment 4 is the best reflection of gene expression. With this prior distribution,
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Table 6.5: Expected value of ∆g and P(∆g > 0) for Gene 3, Gene 4, and Gene 5
using four different priors. The expected value of ∆g varies with the choice of prior
distributions for all three genes. The P(∆g > 0) also differs for all three genes, though
more so for Gene 5 than for Gene 3 or Gene 4.
Gene 3
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior 3.455 0.603
Power Prior
0.873 0.718
Empirical Prior
2.061 0.809
Flat Priors
3.802 0.798
Gene 4
Prior Distribution E(∆) P(∆g > 0)
Informative Prior -38.21 0.013
Power Prior
-1.264 0.203
Empirical Prior
-3.411 0.312
Flat Priors
-3.461 0.321
Gene 5
Prior Distribution E(∆) P(∆g > 0)
Informative Prior -15.74 0.059
Power Prior
-1.273 0.223
Empirical Prior
-4.366 0.384
Flat Priors
-4.394 0.387

Figure 6.4: Prior distributions for Gene 4 and Gene 5. The informative prior is shifted
to the left for both genes, whereas the power and empirical priors are closer to zero.

49

P(∆g > 0) is 0.232 and is therefore not called differentially expressed. The power
prior combines the information from all four previous experiments. Besides Experiment 3, neither Gene 4 nor Gene 5 has strong evidence for differential expression;
therefore, the posterior is shifted closer to zero.
Table 6.6: Estimated value of ∆0 for each of the four previous experiments for Gene
4 and Gene 5.
∆0 (difference in sample means)
Experiment Gene 4 Gene 5
1
0.102
0.051
2
-0.599
0.156
3
-64.8
-12.5
4
0.352
-0.108

Gene 6 and Gene 7 are genes with a low probability of differential expression
based on the case study analysis. The model is applied in the same fashion as in the
previous five genes. The marginal posterior distributions of ∆g using the four prior
distributions for Gene 6 and Gene 7 are shown in Figure 6.5. These distributions
have the same center, aside from the informative prior for Gene 7. The informative
prior using the experiment by Moggs et al. (2005) shifts the posterior of ∆g down
by about 5 gene expression units. The spread is different across the choice of priors.
The power prior has the smallest spread, the empirical prior and flat priors have the
largest spread, and the informative prior has a moderate spread. The choice of prior
distribution does not affect the mean for ∆g and P(∆g > 0) as much as it affects the
differentially expressed genes. The means and probabilities are shown in Table 6.7.
Finally, Gene 8, Gene 9, and Gene 10 are moderately expressed genes; that is,
these genes are near the boundary for differential expression. The Perl script returns
text files of expression values for the same four experiments as in the analysis of
all previous genes. The marginal posterior distribution for ∆g using all four prior
distributions for Gene 8, Gene 9, and Gene 10 are similar to each other (see Figure
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Figure 6.5: Marginal posterior distribution of ∆g for Gene 6 and Gene 7 using four
different priors. The marginal posteriors for both Gene 6 and Gene 7 are as expected:
they are centered around zero and the spread increases as the amount of information
in the prior decreases.

Table 6.7: Expected value of ∆g and P(∆g > 0) for Gene 6 and Gene 7 using three
different priors. While the estimates of the expected value of ∆g and P(∆g > 0)
change with the choice of prior distributions, the difference is not as dramatic as with
the differentially expressed genes.
Gene 6
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior -0.640 0.465
Power Prior
-0.606 0.357
Empirical Prior
0.027 0.507
Flat Priors
0.072 0.524
Gene 7
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior -4.539 0.368
Power Prior
-0.645 0.343
Empirical Prior
0.085 0.505
Flat Priors
0.044 0.523

6.6). The posteriors for Gene 8 and Gene 10 are almost identical. The marginal
posterior for Gene 9 using the informative prior is slightly shifted to the left. Also, for
both Gene 9 and Gene 10, the empirical prior is visibly more peaked than the posterior
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using the flat priors. The estimates of the expected value for ∆g and P(∆g > 0) are
affected by the choice of prior distribution, as seen in Table 6.8.
Another common concern about the Bayesian methodology for microarray analysis is that the prior distribution swamps the data. For the three moderately expressed
genes, Gene 8, Gene 9, and Gene 10, the informative priors have no greater impact
than the flat priors.

Figure 6.6: Marginal posterior distribution of ∆g for Gene 8, Gene 9, and Gene 10
using four different priors. The posteriors using the power prior and the empirical
prior and flat priors are similar for all three genes. The informative prior shifts slightly
for Gene 9 and the spread is much closer to that of the flat priors and empirical prior.
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Table 6.8: Expected value of ∆g and P(∆g > 0) for Gene 8, Gene 9, and Gene 10
using four different priors. There are more detectable differences in the expected
value of ∆g and the P(∆g > 0) than with the equivalently expressed genes, but the
changes are not as radical as with the differentially expressed genes.
Gene 8
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior 1.114 0.635
Power Prior
0.995 0.737
Empirical Prior
1.029 0.714
Flat Priors
1.019 0.697
Gene 9
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior -6.739 0.228
Power Prior
-1.949 0.105
Empirical Prior
-0.777 0.317
Flat Priors
-0.787 0.355
Gene 10
Prior Distribution E(∆g ) P(∆g > 0)
Informative Prior 2.623 0.679
Power Prior
1.695 0.857
Empirical Prior
1.424 0.818
Flat Priors
1.404 0.839

For a given gene, the Perl script retrieves the expression values for each sample
of the historical studies. The model returns marginal posterior distributions for ∆g
using all three proposed prior distributions. The center of the marginal posterior
distributions is not as affected by the choice of prior distribution as the spread. For
all ten genes, the spread of the posterior increases as the choice of prior moves from the
power prior to the informative prior and from the informative prior to the empirical
prior. The estimates of the expected value of ∆g and P(∆g > 0) are also affected by
the choice of priors. The recommended prior distribution for all cases is the power
prior. This prior uses information from multiple previous experiments and decreases
the variance of the marginal posteriors. The informative prior provides information
that is ignored by the flat priors, but it disregards other previous experiments. One
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possible variation of the informative prior is estimating the parameters of the prior on
∆ by the mean and variance of the difference in sample means of the four experiments.
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7. CONCLUSIONS

Bayesian models are ideal for the analysis of microarray studies because of the
ability to integrate prior knowledge. Most current alternate approaches do not include
the information about previous studies in the microarray analysis. The approach
proposed in this thesis uses a Perl script to mine GEO for previous experiments
to build prior distributions. Four prior distributions are explored: a power prior
distribution using historical studies as proposed by Ibrahim and Chen (2000), an
informative prior using one historical study to estimate the hyperparameters, a prior
with data-driven hyperparameters, and flat priors. A model is proposed similar to
the two sample Bayesian t-test presented in Fox and Dimmic (2006) is proposed to
detect differentially expressed genes. The process is applied to ten genes from a breast
cancer experiment. The script and the model perform as expected.
The model chosen is simple, yet effective. A grand hierarchical model that combines all of the information of the current and the past experiments could have been
proposed. While this plan may increase the power to detect differentially expressed
genes, there are many drawbacks. One major problem with a hierarchical model combining multiple studies is the difficulty of keeping track of all the levels of replication.
Housekeeping can prove to be a daunting task with multiple genes from multiple
arrays within each of many studies while also accounting for any missing expression
levels, arrays, or replicates. Another difficulty with the hierarchical approach is the
choice of historical studies to include. These experiments are likely informative about
the same basic biological process, but they may target different populations of people
or include some different treatments or replicates. They may also be investigating a
different set of genes, which then requires decreasing the number of genes analyzed
to a group of common genes from all studies included. That is why, in this work, the
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historical experiments are used to build a prior distribution.
The results of the analysis imply that the choice of prior distribution does affect
the marginal posterior distribution of the difference in means. There are noticable
differences in the spread of the posteriors of all three types of genes. The power prior
gives the posterior distribution with the smallest spread, and the empirical prior
gives the posterior distribution with the largest spread. The informative prior gives
posteriors with a spread somewhere between those given by the the power prior and
the empirical prior. The estimate of the expected value of the difference also changes
between the choices of prior distributions. This change is most apparent in the genes
that are differentially expressed. The informative prior, as defined here, is heavily
sensitive to the choice of the historical study used to estimate the parameters. The
power prior is recommended as the prior distribution because of the incorporation of
multiple previous studies.
The prior distributions for the proposed model are more informative than a
flat prior on the difference in means. However, elicitation is an iterative process. In
an ideal world, this prior would be a starting point. An expert would be consulted
and the prior would be modified using elicitation methods. Therefore, in reality,
while these priors are one step above a flat prior distribution, there is much room for
improvement and further development of this distribution.
There is other information about the genome that could be included in the
analysis. Some include the proportion of experiments in which the gene is called
differentially expressed, which chromosome the gene is located on, the location of
the gene on the chromosome, whether the gene is from the positive or the negative
strand, the environment of the gene (co-factors), or information about clusters of
genes that work together. This information could be included in the construction of
a prior distribution on the probability a given gene is differentially expressed.
The prior distributions are formed with the output from the Perl script. The
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Perl script returns the expression values of a given gene from each sample in multiple
relevant previous studies. In the case of the ten chosen genes, these previous studies
are all the same, though uniformity is not required. The script is also able to overcome
obstacles such as different gene accession name forms, different successive genes across
experiments, and genes at the end of the file. However, the script does require user
input in choosing how to split the data for each experiment. Additionally, the script
only works for one gene. Future work will generalize the script to run without user
input for all the genes in the breast cancer experiment. Also, because the script is
currently specific to the case study experiment, there is future work in creating a
script that follows the entire procedure for any given experiment.
This work provides a program to mine previous microarray studies to build
informative priors for a Bayesian analysis. It presents a framework for easily incorporating genomic knowledge into an analysis. The informative priors investigated are
shown to maintain objectivity and swamp the data no more than the flat priors. The
informative prior estimated with data from one historical experiment exhibits an improvement in inference on genes with a moderate difference in expression. Combining
information from multiple historical studies, as with the power prior, is preferred over
prior parameter estimation using one previous study. With future work, this method
can be generalized for use in any given experiment. The resulting list of differentially
expressed genes will be more accurate and, consequently, help move genomic research
forward.
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A. PERL SCRIPT

#!/usr/bin/perl -w
use WWW::Mechanize;
use HTML::TokeParser;
my $gene = "211120_x_at";
my $agent = WWW::Mechanize->new();
##Go to GEO Profiles website
$agent->get("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=geo");
##Search for experiments
$agent->set_visible("GEO Profiles","$gene breast cancer estrogen receptor");
$agent->click_button(number=>1);
my $url = "http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?view=data&acc=GSM";
my $coun=1;
##Get titles and GDS numbers
foreach ($agent->links){
if ($_->[0] =~ /dataset/){
$agent->get($_->[0]);
my $stream = HTML::TokeParser->new(\$agent->{content});
$stream->get_tag("html");
$stream->get_tag("head");
$stream->get_tag("meta");
$stream->get_tag("title");
my $gds = $stream->get_trimmed_text("title","/title");
if ($gds =~ m/GDS(.*)$gene/){
$dataset = $1;
chop($dataset);
chop($dataset);
chop($dataset);}
$stream->get_tag("b");
$stream->get_tag("b");
$stream->get_tag("b","/b");
my $title= $stream->get_text("/b","br");
if($title =~ /estrogen receptor/ and $title =~ /breast cancer/ and
$title !~ /tamoxifen/){
##Obtain list of how to split data
my $web = WWW::Mechanize->new();
$web->get("http://www.ncbi.nlm.nih.gov/projects/geo/gds/
gds_browse.cgi?gds=$dataset");
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my @exp;
my $cnt=0;
my $stream = HTML::TokeParser->new(\$web->{content});
while (my $token = $stream->get_tag("input")) {
my $type = $token->[1]{type} || "-";
if ($type =~/HIDDEN/){
my $text = $token->[1]{name} || "-";
if ($text =~ /sub/){
if ($text =~ /allsubnames/){
$stream->get_tag("input");
$stream->get_tag("tr");
$stream->get_tag("td","/td");
$stream->get_tag("td");
$stream->get_tag("td","/td");
$stream->get_tag("td","/td");
$stream->get_tag("td","/td");
$stream->get_tag("td","/td");
$exp[$cnt] =$stream->get_trimmed_text("td","/td");
if ($exp[$cnt] =~/control/){$exp[$cnt] = "control$cnt";}
$cnt=$cnt+1;}
my $value = $token->[1]{value} || "-";
my $file = join("\n","$exp[$cnt-1]","$coun","txt");
open file, ">>$file";
print file "$value\n";
close file;
$count=$count+1;
}}}
##Choose how to split data
my $temp = WWW::Mechanize->new();
print "@exp\n";
print "Choose first group:\n";
my $group1 =<STDIN>;
print "Choose second group:\n";
my $group2 =<STDIN>;
chomp $group1;
chomp $group2;
my $file1= join(".","$group1","$coun","txt");
my $file2= join(".","$group2","$coun","txt");
##Retrieve expression values for group 1
my @gsm1;
open input1,"$file1";
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@gsm1=<input1>;
close input1;
splice(@gsm1, 0, 1);
my @group1;
my $count=0;
foreach $gsm (@gsm1){
my $url2 = join(’’,$url,$gsm);
$temp->get($url2);
my $values = HTML::TokeParser->new(\$temp->{content});
#find table values and save them
if ($values->get_tag("\pre")){
my $title = $values->get_trimmed_text([$endtag]);
if($title =~ m/$gene(.*)\n/) {
my $num = $1;
while($num =~ m/[A-Z]/){
chop($num);}
$group1[$count]=$num;
$count=$count+1;
}}}
##Print to file
my $outfile1 = join("\n", "$group1","$coun","2","txt");
$grp1=join(",",@group1);
open out1,">$outfile1";
print out1 "$grp1";
close out1;
##Retrieve expression values for group 2
my @gsm2;
open input2,"$file2";
@gsm2=<input2>;
close input2;
splice(@gsm2, 0, 1);
my @group2;
my $count=0;
foreach $gsm (@gsm2){
my $url2 = join(’’,$url,$gsm);
$temp->get($url2);
my $values = HTML::TokeParser->new(\$temp->{content});
if ($values->get_tag("\pre")){
my $title = $values->get_trimmed_text([$endtag]);
if($title =~ m/$gene(.*)\n/) {
my $num = $1;
while($num =~ m/[A-Z]/){
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chop($num);}
$group2[$count]=$num;
$count=$count+1;
}}}
##Print to file
my $outfile2 = join(".", "$group2","$coun","2","txt");
$grp2=join(",",@group2);
open out2, ">$outfile2";
print out2 "$grp2";
close out2;}
$agent->back();
$coun=$coun+1;
}}
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